Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 6 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Fennec Pharmaceuticals Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 96
- +12 vs. Q3 2025
- Shares held
- 15.5M
- +1.68M (+12.1%) vs. Q3 2025
- Total value
- $119.6M
- −$10.1M (−7.8%) vs. Q3 2025
- New holders
- 20
- 26 more added
- Sold out
- 8
- 24 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FENC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $175.1M |
| Q1 2026 | 90 | $99.6M |
| Q4 2025 | 96 | $119.6M |
| Q3 2025 | 84 | $129.8M |
| Q2 2025 | 78 | $112.9M |
| Q1 2025 | 68 | $81.6M |
| Q4 2024 | 64 | $101.4M |
| Q3 2024 | 63 | $74.6M |
| Q2 2024 | 64 | $87.7M |
| Q1 2024 | 65 | $161.1M |
| Q4 2023 | 56 | $168.4M |
| Q3 2023 | 55 | $107.6M |
| Q2 2023 | 56 | $124.5M |
| Q1 2023 | 54 | $108.5M |
| Q4 2022 | 43 | $119.5M |
| Q3 2022 | 31 | $92.1M |
| Q2 2022 | 28 | $63.2M |
| Q1 2022 | 28 | $64.1M |
| Q4 2021 | 30 | $49.9M |
| Q3 2021 | 32 | $109.7M |
| Q2 2021 | 39 | $88.0M |
| Q1 2021 | 53 | $89.3M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Fennec Pharmaceuticals Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Franklin Resources Inc | 0 | $0 | 0.00% | −16,978−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −188−100.0% | Sold out |
| Fifth Third Bancorp | 0 | $0 | 0.00% | −158−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −1−100.0% | Sold out |